Mazdutide is a long-acting peptide that acts as a dual agonist on GLP-1 and glucagon receptors, developed for chronic weight management and type 2 diabetes. It is typically administered via once-weekly subcutaneous injection, with dosing often starting at a lower amount and gradually increasing to improve tolerability and efficacy.
- Dual GLP-1 and glucagon receptor agonist.
- Significant weight loss (6-14%) observed in clinical trials.
- Administered once weekly via subcutaneous injection.
- Gradual dose titration is recommended to enhance tolerability.
- Often used for chronic weight management and type 2 diabetes.
Reconstitution
Vial strength
5 mg
Bacteriostatic water
3 mL
Concentration
1.67 mg/mL
1 unit = 0.01 mL = 16.7 mcg
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall, avoiding foaming.
- 3Gently swirl until dissolved; do not shake vigorously.
- 4Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-4 | 2.5 mg | 150 units (1.50 mL) |
| Weeks 5-8+ | 5 mg | 300 units (3.00 mL) |
Protocol detail
| Start | 2.5 mg once weekly for the first 4 weeks to establish tolerability. |
|---|---|
| Increase | Advance to 5 mg weekly at week 5 and maintain for the remainder of the protocol (weeks 5–12+). |
| Frequency | Once per week (subcutaneous injection). |
| Cycle Length | Minimum 8 weeks; clinical evidence supports 12–48 week protocols. |
| Timing | Administer on the same day each week; rotate injection sites to avoid irritation. |
Overview at a glance
| Goal | Support chronic weight management and metabolic improvement through dual GLP‑1/glucagon receptor activation. |
|---|---|
| Schedule | Once-weekly subcutaneous injections for a minimum of 8–12 weeks. |
| Dose Range | 2.5–6 mg weekly with gradual titration; advanced protocols may reach 10 mg. |
| Reconstitution | 3.0 mL per 5 mg vial (~1.67 mg/mL) for standard dosing; 2.0 mL for higher concentrations if needed. |
| Storage | Lyophilized frozen at -20 °C (-4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); discard after 28 days. |
How it works
Mazdutide acts as a dual agonist on both GLP-1 and glucagon receptors, offering a combined effect distinct from single-target GLP-1 agonists. This dual action helps suppress appetite and lower glucose levels through GLP-1 activation, while also enhancing energy expenditure via glucagon activation. Clinical trials have demonstrated significant weight loss, ranging from 6.7% to 14% over 24-48 weeks, and improved HbA1c in type 2 diabetes. Its extended half-life allows for convenient once-weekly dosing, providing consistent pharmacologic exposure to maximize its metabolic benefits.
Reported effects
- Significant body weight reduction (6–14%) in obesity trials.
- Improved HbA1c (~1.7% reduction) in type 2 diabetes.
- Favorable metabolic effects, including improved lipid profiles.
- Convenient once-weekly dosing for better adherence.
Reported side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation), usually mild-to-moderate.
- Injection-site reactions (redness, swelling, mild discomfort).
- Increased risk of GI side effects with higher doses (e.g., above 6 mg weekly).
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) or below in dry, dark conditions; protect from moisture.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use bacteriostatic water for multi-dose stability; discard after 28 days or if cloudiness/particulates appear. Do not freeze reconstituted solution.
Supplies
| Peptide vials | 6 vials for 8 weeks (2 vials for weeks 1-4, 4 vials for weeks 5-8); 10 vials for 12 weeks; 14 vials for 16 weeks |
|---|---|
| Insulin Syringes (U-100, 1 mL or 3 mL) | One per week (e.g., 8 syringes for 8 weeks) |
| Bacteriostatic Water (10 mL bottles) | 2 bottles for 8 weeks (18 mL total); 3 bottles for 12 weeks; 5 bottles for 16 weeks |
| Alcohol Swabs | Two per week (e.g., recommend a 100-count box) |
Important notes
- Use a new sterile insulin syringe for each weekly injection and dispose of it in a sharps container.
- Rotate injection sites weekly (abdomen, thighs, upper arms) to minimize local irritation.
- For doses requiring >3 mL volume, split into two separate injections at different sites.
- Allow reconstituted vials to reach room temperature before drawing the dose.
- Document dose, injection site, and any side effects to track response.
Frequently asked questions
What is the primary benefit of Mazdutide's dual GLP-1/glucagon agonism?
The dual agonism combines the appetite suppression and glucose-lowering effects of GLP-1 with the metabolic boosting and energy expenditure from glucagon activation, leading to more robust weight loss and metabolic improvements compared to single-target therapies.
Why is gradual dose titration recommended for Mazdutide?
Gradual dose titration is suggested to improve tolerability and reduce the likelihood of gastrointestinal side effects, such as nausea or vomiting, which are common when initiating treatment with GLP-1 receptor agonists.
How often should Mazdutide be injected?
Mazdutide has an extended half-life, which allows for convenient once-weekly subcutaneous injections. It is generally recommended to administer it on the same day each week.
Can Mazdutide be used for type 2 diabetes management?
Yes, clinical trials have shown that Mazdutide can significantly improve HbA1c levels in individuals with type 2 diabetes, in addition to promoting weight loss. This makes it a potential treatment option for managing both conditions.
Educational reference only. These figures summarise how Mazdutide is commonly described in research literature and supplier documentation, including the Mazdutide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Mazdutide (10 mg Vial)
Dual GLP-1/glucagon agonist for weight loss and metabolic improvement.
Semaglutide (10 mg Vial)
Weekly GLP-1 for weight loss and metabolic health.
Semaglutide (20 mg Vial)
Weekly GLP-1 agonist for weight loss and glucose control.
Semaglutide (30 mg Vial)
Weekly GLP-1 agonist for weight loss and glucose control.